BTAI SEC Form 4 filings
Bioxcel Therapeutics, Inc. Latest Insider Trading Activity
The most recent employee insider trading activity for Bioxcel Therapeutics, Inc. was on May 20, 2026, when Mehta Vimal (CEO and President) reported a sale of 19,419 shares at $1.09 per share. For the past 715 days, BTAI has had 13 total insider transactions represented in the displayed records. This page shows up to the 10 most recent SEC Form 4 filing records on a 6-hour delay. Sign up for real-time updates and access to 20 years of historic insider trading data.
Insider Trading For BTAI Charted on Daily Candles. Scroll left or zoom out to load earlier candles (up to 2 years).
▲ Insider buy
▼ Insider sale
Loading daily price history…
Charting by TradingView Lightweight Charts
| Ticker | Filing Date | Transaction Date | Company | Insider | Title | Transaction | Trade Count | Shares | Avg. Price | Total Value | Position Size Change | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10b5-1: Scheduled Form 4 Transaction BTAI | 2026-05-22 | 2026-05-20 | Bioxcel Therapeutics, Inc. | Mehta Vimal | CEO and President | Sell | 1 | 19,419 | $1.09 | $21,166.71 | 21.81% | View Filing |
| 10b5-1: Scheduled Form 4 Transaction BTAI | 2026-05-22 | 2026-05-20 | Bioxcel Therapeutics, Inc. | Yocca Frank | Chief Scientific Officer | Sell | 1 | 6,845 | $1.09 | $7,461.05 | 20.73% | View Filing |
| 10b5-1: Scheduled Form 4 Transaction BTAI | 2026-05-22 | 2026-05-20 | Bioxcel Therapeutics, Inc. | Rodriguez Javier | Officer | Sell | 1 | 6,560 | $1.08 | $7,084.80 | 19.66% | View Filing |
| 10b5-1: Scheduled Form 4 Transaction BTAI | 2026-05-22 | 2026-05-20 | Bioxcel Therapeutics, Inc. | Steinhart Richard I | Chief Financial Officer | Sell | 1 | 6,845 | $1.09 | $7,461.05 | 20.65% | View Filing |
| 10b5-1: Scheduled Form 4 Transaction BTAI | 2024-12-17 | 2024-12-16 | Bioxcel Therapeutics, Inc. | O'Neill Vincent | Officer | Sell | 1 | 165 | $0.35 | $57.75 | 0.82% | View Filing |
| 10b5-1: Scheduled Form 4 Transaction BTAI | 2024-12-17 | 2024-12-16 | Bioxcel Therapeutics, Inc. | Mehta Vimal | CEO and President | Sell | 2 | 3,117 | $0.36 | $1,122.12 | 2.52% | View Filing |
| 10b5-1: Scheduled Form 4 Transaction BTAI | 2024-12-17 | 2024-12-16 | Bioxcel Therapeutics, Inc. | Steinhart Richard I | Chief Financial Officer | Sell | 2 | 577 | $0.36 | $207.72 | 1.35% | View Filing |
| 10b5-1: Scheduled Form 4 Transaction BTAI | 2024-12-17 | 2024-12-16 | Bioxcel Therapeutics, Inc. | Yocca Frank | Chief Scientific Officer | Sell | 2 | 430 | $0.35 | $152.55 | 0.73% | View Filing |
| 10b5-1: Scheduled Form 4 Transaction BTAI | 2024-10-03 | 2024-10-03 | Bioxcel Therapeutics, Inc. | Wiley Matthew T. | Chief Commercial Officer | Sell | 1 | 6,272 | $0.55 | $3,449.60 | 24.81% | View Filing |
| 10b5-1: Scheduled Form 4 Transaction BTAI | 2024-10-03 | 2024-10-03 | Bioxcel Therapeutics, Inc. | Rodriguez Javier | Officer | Sell | 1 | 6,863 | $0.55 | $3,774.65 | 22.40% | View Filing |
⚠️ THE SAMPLE ABOVE IS DEFERRED BY 6 HOURS ⚠️
Start your 2-week, no-credit-card free trial today to receive get down to the second insider trading updates in this directory or email.
Pricing
Free Trial
10 trading days$0
Explore every Premium feature before you pay.
- Full platform access
- 10 trading days
- No credit card required
- 20 years of alert history
- Live alert directory updates
Standard Monthly
Scheduled$19.99 / month
Scheduled alerts with complete trade context.
- Email and Telegram delivery
- Alert intervals from every sixty minutes to once daily
- Filter by insider title, buy/sell, transaction value, DRIP, ESPP, 10b5-1, and tax liability coverage transfers
- Highlighted cluster transactions and SEC filing links
- Access to the alert directory hourly refreshes
Premium Monthly
Recommended$29.99 / month
Fastest alerts with ticker-level control.
- Everything in Standard
- Instant delivery detection-to-outbound time averages 3.00 seconds
- Alert intervals starting from one minute
- Real time alert directory updates
Student discount: Customers who sign up with a verified .edu email address receive 50% off for the first four years. On monthly plans, the first month is the full 75% off.
Alerts are based on public SEC filings and are provided for informational purposes only; they do not constitute financial advice.